4 insiders buy $72 mil of Micro-Cap Biotech

Here are three stocks recently purchased by C-level insiders Here are three stocks recently purchased by C-level insiders                                                                                                      You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here. Dear Fellow Investor, Investors should always be on the lookout for insights that could give them an edge in the stock market, and one potential source of such information is insider buying activity. When company insiders, such as executives or board members, buy shares of a company's stock, it can be seen as a vote of confidence in the company's prospects. Publicly available insider buying information can provide valuable clues about which stocks may be worth considering for investment. Here are three stocks recently purchased by C-level insiders - Lexicon Pharmaceuticals, Inc. – SYM: LXRX Recent Price: $2.30 Insider Action: 4 insiders buy $72 mil in shares Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.  === [Collect 5 dividend checks per week]( Hi, I'm Tim Plaehn, and I just did the math in my own, real-money portfolio. I'll be collecting 70 dividend checks this quarter. That's nearly 5 per week on average. Automatically… no trading, no options, no work. You don't need a lot of money. You can be retired or near retirement... Either way, I'll show you my #1 plan to quickly collect dividends like clockwork from high-quality, cash-flowing business. [Click here to learn how to collect up to 5 dividends a week.]( === CalciMedica, Inc. – SYM: CALC Recent Price: $4.07 [Get Insider Action Here ]( Description: CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California. === [WARNING: Mandatory U.S. Dollar Recall to Begin on July 26?]( [teeka]( If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars. [Click here to see the three simple steps you can take now to protect your life savings.]( === Eyenovia, Inc. – SYM: EYEN Recent Price: $2.45 [Get Insider Action Here ]( Description: Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York. === [Forget Fusion... This REAL Nuclear Breakthrough Could Mean 10X Gains]( [oxford nuclear]( A real nuclear miracle is about to take Wall Street by surprise... Because an energy breakthrough could 10X this $1 stock over five years. After a key August announcement... you may miss your chance at a piece of the action. [Get the Details Here (Before You're Too Late!)]( "The Buck Stops Here" [youtube button]( [facebook button]( [instagram button]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2023 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](